MCE products for research use only. We do not sell to patients.

WKYMVm

MCE China：WKYMVm

Brand：MedChemExpress (MCE)

Cat. No.HY-P1120

CAS：187986-17-0

Purity：99.88%

Storage：Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.

In Vitro：WKYMVm (0-5 μmol/L; 2 h) inhibits the production of inflammatory cytokines (TNF-α, IL-6 and IL-1β) in LPS (HY-D1056) treated microglia [3]. WKYMVm (1-100 µM; 0-24 h) can increase FPR2 mRNA level and ERK phosphorylation level in HUVECs cells, promote HUVECs tube formation and cell proliferation[4].

In Vivo：WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model[3]. WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice[4]. WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models[5].

IC50 & Target：FPR1, FPRL1[1], FPRL2[2] Cellular Effect Cell Line Type Value Description References

Sequence：Trp-Lys-Tyr-Met-Val-{d-Met}-NH2

Hot selling product：4-Chloro-7H-pyrrolo[2,3-d]pyrimidine  | SPB  | Tamibarotene  | CITCO  | Relugolix  | Cefoperazone  | LCMV gp33-41  | H-Phe(4-Ac)-OH  | 3-Nitropropanoic acid  | Demeclocycline

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93.  [Content Brief]

[2]. Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6.  [Content Brief]

[3]. Zhang W, et al. WKYMVm/FPR2 Alleviates Spinal Cord Injury by Attenuating the Inflammatory Response of Microglia. Mediators Inflamm. 2022 Jul 27;2022:4408099.  [Content Brief]

[4]. Kim YE, et al. WKYMVm hexapeptide, a strong formyl peptide receptor 2 agonist, attenuates hyperoxia-induced lung injuries in newborn mice. Sci Rep. 2019 May 2;9(1):6815.  [Content Brief]

[5]. Kang JH, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling. J Cell Mol Med. 2023 Sep;27(18):2782-2791.  [Content Brief]

[6]. Yang Y, et al. WKYMVm Works by Targeting Immune Cells. J Inflamm Res. 2023 Jan 6;16:45-55.  [Content Brief]

[7]. Ma H, et al. Therapeutic potential of WKYMVm in diseases. Front Pharmacol. 2022 Sep 2;13:986963.  [Content Brief]